ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Cytotoxic Cells"

  • Abstract Number: 0080 • ACR Convergence 2024

    Enhanced Cytotoxicity of Aging Associated NKG2C+ CD8+ T Cells in Ankylosing Spondylitis via HLA-B27

    Kunhai Tang, Xiaobei Ma, Jian Gao, Feng Qian, Qi Zhu, Jiucun Wang and Jing Liu, Fudan University, Shanghai, China (People's Republic)

    Background/Purpose: Ankylosing spondylitis (AS) is an immune-related chronic inflammatory disease characterized by inflammatory pain in the lower back and spinal ankylosing, accompanied by immune system disorders, such…
  • Abstract Number: 0835 • ACR Convergence 2024

    Effective Engineering of CD8+ T Cells from Autoimmune Disease Patients Utilizing a CD8-Targeted Lipid NanoparticleEncoding an Anti-CD19 CAR mRNA(CPTX2309)

    Yan Zhang1, Brittany Ross1, Diana Galvan1, Yanjie Bao1, Daiki Matsuda1, Shaun Grosskurth1, Iago Pinal-Fernandez2, Maria Casal-Dominguez3, Gregor Adams1, Michael Rosenzweig1, Ramin Farzaneh-Far1, Priya Karmali1, Adrian Bot1, Andrew Mammen2 and Haig Aghajanian1, 1Capstan Therapeutics, San Diego, CA, 2NIH, Bethesda, MD, 3NIH, Bathesda, MD

    Background/Purpose: Ex vivo chimeric antigen receptor (CAR) T cell therapies have revolutionized cancer treatment and are demonstrating durable clinical efficacy in various autoimmune disease (AID)…
  • Abstract Number: 1837 • ACR Convergence 2024

    Baseline Multiome Sequencing of CD45RO+CD45RA-CD4+ T Cell Reveals Distinct Immune Profiles Associated with Subsequent Response to Secukinumab Treatment

    Addison Pacheco1, Zoya Qaiyum2, Fataneh Tavasolian3, Melissa Lim4, Michael Tang1 and Robert Inman1, 1University Health Network, Toronto, ON, Canada, 2Krembil Research Institute, Toronto, ON, Canada, 3Krembil Research Institute - the University Health Network, Toronto, ON, Canada, 4University of Toronto, Toronto, ON, Canada

    Background/Purpose: Our study aims to discriminate immune profiles between secukinumab responders (SEC-R) and nonresponders (SEC-NR) in axial spondyloarthritis (axSpA) patients before biologic treatment.Methods: CD45RO+CD45RA-CD4+ T…
  • Abstract Number: 1862 • ACR Convergence 2024

    Folate Receptor β CAR-Tregs Induce Monocyte Apoptosis and Immune Polarization: Potential for Therapeutic Application in Rheumatoid Arthritis

    Xiangni Wu1, Pin-I Chen2, Magdiel Pérez Cruz3, Kent Jensen3 and Everett Meyer3, 1UMKC, KANSAS CITY, MO, 2Department of Medicine, Division of Blood and Bone Marrow Transplantation and Cell Therapy, Stanford University School of Medicine, Stanford, CA, USA., Sunnyvale, CA, 3Department of Medicine, Division of Blood and Bone Marrow Transplantation and Cell Therapy, Stanford University School of Medicine, Stanford, CA, USA., Stanford

    Background/Purpose: Rheumatoid arthritis (RA) affects approximately 1.3 million adults in the United States, causing significant morbidity and economic burden. Current treatments reduce inflammation and slow…
  • Abstract Number: 0087 • ACR Convergence 2023

    Immune Checkpoint Inhibitor Therapy Expands an Activated, anti-PD-1 Drug-bound CD8 T Cell Population That Is Clonally Linked in Blood and Synovial Fluid of ICI-arthritis Patients

    Kathryne Marks1, Anvita Singaraju2, Runci Wang3, Ifeoluwakiisi Adejoorin1, Miriam Fein2, Michael Postow4, Karmela Kim Chan2, Anne Bass5, Laura Donlin2 and Deepak Rao1, 1Brigham and Women's Hospital, Boston, MA, 2Hospital for Special Surgery, New York, NY, 3Renji hospital, Shanghai Jiaotong University, Pudong Xinqu, China, 4Memorial Sloan Kettering Cancer Center, New York, NY, 5Hospital for Special Surgery, Weill Cornell Medicine, New York, NY

    Background/Purpose: Immune checkpoint inhibitor (ICI) therapies used to treat cancer can induce immune related Adverse events (irAEs) such as ICI-induced arthritis (ICI-arthritis). We have previously…
  • Abstract Number: 0092 • ACR Convergence 2023

    Multi-omics Immune Profiling of Cytotoxic T Cells from Ankylosing Spondylitis Patients Identified a Subset of Clonally Exapnded CTLs That Evade Immune Exhaustion

    Michael Tang1, Zoya Qaiyum2, Melissa Lim1 and Robert Inman1, 1University Health Network, Toronto, ON, Canada, 2Krembil Research Institute, Toronto, ON, Canada

    Background/Purpose: Sustained chronic inflammation in the spine and of the sacroiliac joints is a key feature in Ankylosing Spondylitis (AS). A central role of CTL…
  • Abstract Number: 0093 • ACR Convergence 2023

    Single Cell RNA-seq and Mass Cytometry Reveal a Cytotoxic CD8 Effector T Cell Population Associated with Interstitial Lung Disease in Systemic Sclerosis Patients

    Ye Cao1, Takanori Sasaki2, Richard Ainsworth3, Kim Taylor4, Nunzio Bottini5, Mehreen Elahee6, Edy Kim7, Francesco Boin3 and Deepak Rao7, 1Brigham and Women's Hospital, Boston, MA, 2Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 3Cedars-Sinai Medical Center, Los Angeles, CA, 4University of California San Francisco, San Francisco, CA, 5University of California, San Francisco, CA, 6University of Pittsburgh Medical Center, Pittsburgh, PA, 7Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Interstitial lung disease (ILD) is a major cause of morbidity and mortality in systemic sclerosis (SSc). We aimed to identify features of circulating immune…
  • Abstract Number: 1662 • ACR Convergence 2023

    Chronic Excess IL-18 Induces NK Deficiency, but Drives Hyperinflammation via CD8 T-cell Cytokine Overproduction and Selective Immunodeficiency

    Jemy Varghese1, Scott Canna1, Emily Landy2, Laurence Eisenlohr1, Elise Peauroi3, Vinh Dang1, Anastasia Frank-Kamenetskii4 and Jeremy Morrissette5, 1Children's Hospital of Philadelphia, Philadelphia, PA, 2University of Pittsburgh, Pittsburgh, PA, 3University of Pennsylvania, Philadelphia, PA, 4CHOP/UPENN, Philadelphia, PA, 5University of Pennsylvania - Perelman School of Medicine, Philadelphia, PA

    Background/Purpose: Systemic Juvenile Idiopathic Arthritis (SJIA) and Macrophage Activation Syndrome (MAS) are associated with highly elevated peripheral blood levels of the inflammasome-activated cytokine IL-18 and…
  • Abstract Number: 1790 • ACR Convergence 2023

    Expansion of CD8+ TCRVβ9+ T Cells in the Peripheral Blood of HLA-B27+ Patients with Axial Spondyloarthritis

    Caroline Bauchiero1, Micah Lefton1, Stephanie Sinnappan2, Jeffrey Sparks3 and Joerg Ermann4, 1Brigham and Women's Hospital, Boston, MA, 2Columbia University, New York, NY, 3Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, 4Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: Studies in human HLA-B27 transgenic rats largely discredited the idea that CD8+ T cells are key drivers of disease in axial spondyloarthritis (axSpA). However,…
  • Abstract Number: 1748 • ACR Convergence 2022

    Deep Immune Profiling of Cytotoxic T Cells (CTL) from Patients with Ankylosing Spondylitis Revealed a Subset of CTL Co-Expressing PD-1 and TIGIT That Resists Immune Exhaustion

    Michael Tang1, Addison Pacheco2, Zoya Qaiyum3, Melissa Lim1 and Robert Inman1, 1University Health Network, Toronto, ON, Canada, 2University of Toronto, Toronto, ON, Canada, 3Krembil Research Institute, Toronto, ON, Canada

    Background/Purpose: Unresolved, chronic inflammation is a key feature of Ankylosing Spondylitis (AS) yet the immunological events perpetuating remain unclear. The strongest genetic association with AS…
  • Abstract Number: 0569 • ACR Convergence 2022

    Cytokine Storm Susceptibility Factors IL-18 and Cytotoxic Impairment Converge on Pathologic CD8 T-cell Hyperactivation

    Emily Landy1, Scott Canna2, Paul Tsoukas3, Vinh Dang2 and Jemy Varghese2, 1University of Pittsburgh, Pittsburgh, PA, 2Children's Hospital of Philadelphia, Philadelphia, PA, 3The Hospital for Sick Children, Toronto, ON, Canada

    Background/Purpose: Mounting evidence suggests partial defects in cytotoxicity-related genes may promote hyperinflammation in Macrophage Activation Syndrome (MAS) patients, who uniformly have highly-elevated IL-18. In mice,…
  • Abstract Number: 0628 • ACR Convergence 2022

    A Positive-feedback Model for the Contribution of Virus-Specific T Cells to the Development of Rheumatoid Arthritis

    Hendrik Nel1, Pascale Wehr2, Christopher Andoniou3, Iona Schuster3, Stephanie Gras4, Helen McGuire5, Helen Weedon6, Annabelle Small7, Katie Lowe7, Mariapia Degli-Esposti3, Mihir Wechalekar8 and Ranjeny Thomas9, 1University of Queensland, Brisbane, Australia, Woolloongabba, Australia, 2University of Queensland Diamantina Institute, Brisbane, Australia, 3Infection and Immunity Program and Department of Microbiology, Biomedicine Discovery Institute, Monash, Australia, 4Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Australia, 5The University of Sydney, Charles Perkins Centre, Camperdown, Australia, 6Flinders University of South Australia, Bedford Park, Australia, 7Flinders University, Adelaide, Australia, 8Flinders Medical Centre, Bedford Park, Australia, 9University of Queensland, Brisbane, Australia

    Background/Purpose: Rheumatoid Arthritis (RA) is associated with specific HLA-DR genotypes with an emphasis on the role of CD4+ effector-memory T cells (Tem) in disease pathogenesis.…
  • Abstract Number: 1124 • ACR Convergence 2022

    CD4+ Cytotoxic T Lymphocytes (CTL) Are Present in Sjögren’s Disease Minor Salivary Glands and Associate with Markers of Epithelial Cell Damage near Infiltrates

    Michelle Joachims1, Chuang Li1, Joshua Rusbuldt2, Ben Fowler1, Astrid Rasmussen1, Kiely Grundahl1, R. Hal Scofield3, Kathy Sivils4, Christopher Lessard1 and A. Darise Farris1, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Janssen Pharmaceutical Companies of Johnson & Johnson, Spring House, PA, 3University of Oklahoma Health Sciences Center, Oklahoma City, OK, 4Janssen Research and Development, LLC, Spring House, PA

    Background/Purpose: CD4+ T cells dominate focal lymphocytic infiltrates in Sjögren's disease (SjD), but their differentiation states have remained unclear. Here, we used single cell (sc)RNAseq…
  • Abstract Number: 1560 • ACR Convergence 2022

    Modulation of NKG2D Expression on NK, NKT and CD8+ T Lymphocytes by in Vitro Treatments of Immune Cells from Patients with Behçet Disease

    Martina Bonacini1, Francesco Muratore1, Giovanna Restuccia2, Laura Albertazzi2, Piera Zaldini2, Luca Cimino3, Rossana Colla2, Alessandro Zerbini1, Carlo Salvarani4 and Stefania Croci1, 1Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy, 2Azienda Unità Sanitaria Locale – IRCCS di Reggio Emilia, Reggio Emilia, Italy, 3Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, University of Modena and Reggio Emilia, Reggio Emilia, Italy, 4Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Università di Modena e Reggio Emilia, Reggio Emilia, Italy

    Background/Purpose: Behçet disease (BD) is an inflammatory chronic disease characterized by alternation of active and inactive phases. Steroids, Colchine, Azathioprine (Aza) and interferon α are…
  • Abstract Number: 1702 • ACR Convergence 2022

    Targeting CD6-CD318 Axis with UMCD6 (anti-CD6) Enhances in Vivo Killing of Cancer Cells Through Direct Activation of NK Cells

    Mikel Gurrea-Rubio1, Qi Wu1, Eliza Pei-Suen Tsou1, M. Asif Amin1, Phillip Campbell1, Peggy Randon1, Matthew Lind1, Sarah Ory1, Camila Amarista1, Sirapa Vichaikul2, Jeffrey Ruth1, Feng Ling3 and David Fox1, 1University of Michigan, Ann Arbor, MI, 2Michigan Medicine, Howell, MI, 3Cleveland Clinic, Cleveland, OH

    Background/Purpose: Immune checkpoint inhibitors represent a major advance in cancer treatment, but disease prognosis continues to be poor for most patients. Resistance of cancer cells…
  • 1
  • 2
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology